Clinical Trials Browser

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00019448 2024-03-04

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

BreastDermatologicGastrointestinalSarcomaThoracic

Uveal Melanoma, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Eye Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Skin Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Breast Neoplasms, Male, Muscle Neoplasms, Genetic Diseases, Inborn, Histiocytoma, Malignant Fibrous

Clinical Trials

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Metastatic Cancer

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Drosophila-generated CTL

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence